WCN26-4276 Gene expression levels of CD40L, OX40L, TNFa, or BTK are inversely related to likelihood of complete remission in patients with FSGS and MCD

Read full text Summarise with VIRAT
Authors: Angela Hu, Sean F. Eddy, Khun Zaw Latt, Wenjun Ju, Karen E. Ocwieja, Dobrin Draganov, Pronabesh DasMahapatra, Shiguang Liu, Sagar U. Nigwekar, Matthias Kretzler
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Heterogeneity in the immune mediated mechanisms underlying the pathogenesis of focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD) poses challenges to identifying therapeutic targets. To address this heterogeneity and potentially advance precision medicine approaches in FSGS/MCD, we identified for further study 3 investigational agents, targeting distinct immune pathways associated with FSGS/MCD: Bruton's tyrosine kinase (BTK), CD40 ligand (CD40L), OX40 ligand (tumor necrosis factor superfamily member 4 (TNSF4)), and tumor necrosis factor α (TNFα).

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Renal Transplantation Outcomes and Treatments Systemic Lupus Erythematosus Research

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105604–105604
Publication date
25 March 2026
Language
EN